RJA
NXTM

Raymond James & Associates’s NxStage Medical Inc. NXTM Stock Holding History

Raymond James & Associates’s Portfolio NXTM Stock Details NXTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-34,140
Closed -$856K – 3531
2017
Q2 		$856K Buy
34,140
+10,448
+44% +$259K ﹤0.01% 2125
2017
Q1 		$636K Buy
+23,692
New +$654K ﹤0.01% 2242
2016
Q1 		– Sell
-12,228
Closed -$268K – 2990
2015
Q4 		$268K Buy
+12,228
New +$228K ﹤0.01% 2234

Other funds holding NXTM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James & Associates's NXTM Position: Q3 2017 in Review

Raymond James & Associates sold out of NxStage Medical Inc. (NXTM) in Q3 2017, closing a stake of 34,140 shares — an estimated $856K sold.

Raymond James & Associates first reported a position in NXTM in Q4 2015 and held it in 3 quarters. The position peaked at $856K in Q2 2017. 168 funds tracked by Wall St. Rank hold NXTM as of Q3 2017.

  • Raymond James & Associates reported no remaining NxStage Medical Inc. position as of Q3 2017 after selling out during the quarter.
  • Raymond James & Associates sold 34,140 NxStage Medical Inc. shares in Q3 2017, an estimated $856K.
  • Raymond James & Associates first reported a position in NxStage Medical Inc. in Q4 2015 and held it in 3 quarters.
  • Raymond James & Associates's NxStage Medical Inc. position peaked at $856K in Q2 2017.
  • 168 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q3 2017.

Based on Raymond James & Associates's 13F filing for Q3 2017, filed 13 Nov 2017.